서울대학교 생물정보학 협동과정 주최로 세미나를 아래와 같이 열고자 하오니 많은 참여 바랍니다.

세미나는 Zoom을 통한 온라인 강의로 예정되어 있으며 강의에 참여하고자 하시는 분께서는 아래의 링크로 참여 부탁드리겠습니다.

*줌으로 참석하기 위해서는 "참석자로 회의 참가" --> 이름, 성, 이메일 주소, 이메일 주소 확인을 입력하시고 등록하시면 회의 참석이 가능합니다.

일시: 2023년 11월 14일 화요일 오전 11시

연사: 김봉조 과장님 (국립보건연구원)

Zoom link: http://snu-ac-kr.zoom.us/s/99344901481

Title: Genome study of type 2 diabetes using Korea Biobank Array (한국인칩을 이용한 제2형 당뇨병 유전체연구)

Abstract:

Type 2 diabetes (T2D) arises from a complex interplay between genetic and environmental factors. In the past decade, extensive genomic studies on East Asians, including Koreans, have identified numerous loci linked to T2D. Based on polygenic risk scores (PRS) derived from these associations, individuals at high genetic risk exhibit approximately 2-3 times higher prevalence of T2D compared to those in the remaining group. Recent research underscores the significant influence of rare variants with substantial genetic effects, resulting in nearly 50% reduction in T2D prevalence among carriers of the rare allele. Beyond genomics, a healthy lifestyle score (HLS) that integrates individual lifestyle risk factors has been developed to assess T2D risk. Individuals with an ‘unfavorable’ lifestyle display an increased incident of T2D compared with the baseline group. Merging these genetic and environmental risk factors creates an opportunity to stratify individuals at risk of T2D. Indeed, individuals with an unfavorable lifestyle and the top 20% T2D-PRS demonstrate nine times higher T2D incidence than the baseline group. However, rare allele carriers exhibit a reduced risk of prevalent T2D among the intermediate and unfavorable HLS groups compared to the favorable group. By considering the joint impact of common and rare genetic variants alongside lifestyle factors, the predictability of T2D within the Korean population has been enhanced. Classifying individuals based on their genetic composition of common and rare alleles would allow for the categorization of various T2D subtypes, facilitating targeted interventions and personalized treatment options, potentially advancing clinical practice in the future.